Patents by Inventor Rinta Ibuki
Rinta Ibuki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8551522Abstract: A sustained-release formulation is provided comprising a solid dispersion composition comprising a tricyclic compound or a pharmaceutically acceptable salt thereof in a mixture comprising a water-soluble polymer and a water-insoluble polymer, and an excipient.Type: GrantFiled: November 5, 2008Date of Patent: October 8, 2013Assignee: Astellas Pharma Inc.Inventors: Kazunari Yamashita, Eiji Hashimoto, Yukihiro Nomura, Fumio Shimojo, Shigeki Tamura, Takeo Hirose, Satoshi Ueda, Takashi Saitoh, Rinta Ibuki, Toshio Ideno
-
Publication number: 20090074858Abstract: A sustained-release formulation is provided comprising a solid dispersion composition comprising a tricyclic compound or a pharmaceutically acceptable salt thereof in a mixture comprising a water-soluble polymer and a water-insoluble polymer and an excipient.Type: ApplicationFiled: November 5, 2008Publication date: March 19, 2009Applicant: ASTELLAS PHARMA INC.Inventors: Kazunari YAMASHITA, Eiji HASHIMOTO, Yukihiro NOMURA, Fumio SHIMOJO, Shigeki TAMURA, Takeo HIROSE, Satoshi UEDA, Takashi SAITOH, Rinta IBUKI, Toshio IDENO
-
Publication number: 20050169993Abstract: A sustained-release formulation is provided comprising a solid dispersion composition comprising a tricyclic compound or a pharmaceutically acceptable salt thereof in a mixture comprising a water-soluble polymer and a water-insoluble polymer, and an excipient.Type: ApplicationFiled: February 17, 2005Publication date: August 4, 2005Applicant: Fujisawa Pharmaceutical Co., Ltd.Inventors: Kazunari Yamashita, Eiji Hashimoto, Yukihiro Nomura, Fumio Shimojo, Shigeki Tamura, Takeo Hirose, Satoshi Ueda, Takashi Saitoh, Rinta Ibuki, Toshio Ideno
-
Patent number: 6884433Abstract: Sustained release formulation containing tacrolimus or its hydrate is provided. The time (T63.2%) required for 63.2% of the maximum amount of tacrolimus or its hydrate to be dissolved is 0.7 to 15 hours. The time is measured in accordance to the Japanes Pharmacopocia, the 13-th edition, Dissolution Test, No. 2 (Puddles method, 50 rpm) using an aqueous 0.005% hydroxypropyl cellulose solution. This aqueous test solution is adjusted to pH 4.5, accordingly. The formulation further comprises a solid base which is a water-soluble or water-insoluble polymer. The formulation is in the form of a powder, fine powder, granule, tablet or capsule. The formulation is administered to a patient once a day for preventing organ or tissue rejection by transplantation or autoimmune disease. In addition, a solid dispersion composition is provided. The solid dispersion comprises tacrolimus or its hydrate in a mixture containing water-soluble or water-insoluble polymer and an excipient.Type: GrantFiled: April 14, 2003Date of Patent: April 26, 2005Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Kazunari Yamashita, Eiji Hashimoto, Yukihiro Nomura, Fumio Shimojo, Shigeki Tamura, Takeo Hirose, Satoshi Ueda, Takashi Saitoh, Rinta Ibuki, Toshio Ideno
-
Patent number: 6673808Abstract: To provide a pharmaceutical composition comprising a macrolide compound, such as tricyclic compound (I) or its pharmaceutically acceptable salt, a dissolution/absorption promoter, a pharmaceutical base, and optionally a compatibilizing agent and/or a thickener. It is satisfactory in stability and absorption kinetics and/or a low irritation potential.Type: GrantFiled: November 22, 2000Date of Patent: January 6, 2004Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Rinta Ibuki, Fumio Shimojo, Satoshi Ueda, Toshihiko Toyoda, Masayuki Yamanaka, Erika Yoshida
-
Publication number: 20030235614Abstract: Providing an oral formulation of a macrolide compound where the dissolution of the macrolide compound is under sustained release; and a sustained-release formulation containing a composition in solid solution, where the macrolide compound is present at an amorphous state in a solid base.Type: ApplicationFiled: April 14, 2003Publication date: December 25, 2003Applicant: Fujisawa Pharmaceutical Co. Ltd.Inventors: Kazunari Yamashita, Eiji Hashimoto, Yukihiro Nomura, Fumio Shimojo, Shigeki Tamura, Takeo Hirose, Satoshi Ueda, Takashi Saitoh, Rinta Ibuki, Toshio Ideno
-
Patent number: 6586444Abstract: To provide a pharmaceutical composition comprising a macrolide compound, such as tricyclic compound (I) or its pharmaceutically acceptable salt, a dissolution/absorption promoter, a pharmaceutical base, and optionally a compatibilizing agent and/or a thickener. It is satisfactory in stability and absorption kinetics and/or a low irritation potential.Type: GrantFiled: December 7, 2001Date of Patent: July 1, 2003Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Rinta Ibuki, Fumio Shimojo, Satoshi Ueda, Toshihiko Toyoda, Masayuki Yamanaka, Erika Yoshida
-
Patent number: 6576259Abstract: Sustained release formulation containing tacrolimus or its hydrate is provided. The time (T63.2%) required for 63.2% of the maximum amount of tacrolimus or its hydrate to be dissolved is 0.7 to 15 hours. The time is measured in accordance to the Japanese Pharmacopoeia, the 13-th edition, Dissolution Test, No. 2 (Puddle method, 50 rpm) using an aqueous 0.005% hydroxypropyl cellulose solution. This aqueous test solution is adjusted to pH 4.5, accordingly. The formulation further comprise a solid base which is a water-soluble polymer and/or wax. The formulation is in the form of a powder, fine powder, granule, tablet or capsule. Furthermore, the formulation is administered to a patient once a day for preventing organ or tissue rejection by transplantation or autoimmune diseases.Type: GrantFiled: October 17, 2001Date of Patent: June 10, 2003Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Kazunari Yamashita, Eiji Hashimoto, Yukihiro Nomura, Fumio Shimojo, Shigeki Tamura, Takeo Hirose, Satoshi Ueda, Takashi Saitoh, Rinta Ibuki, Toshio Ideno
-
Patent number: 6440458Abstract: Providing an oral formulation of a macrolide compound where the dissolution of the macrolide compound is under sustained release; and a sustained-release formulation containing a composition in solid solution, where the macrolide compound is present at an amorphous state in a solid base.Type: GrantFiled: November 5, 1999Date of Patent: August 27, 2002Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Kazunari Yamashita, Eiji Hashimoto, Yukihiro Nomura, Fumio Shimojo, Shigeki Tamura, Takeo Hirose, Satoshi Ueda, Takashi Saitoh, Rinta Ibuki, Toshio Ideno
-
Publication number: 20020061907Abstract: To provide a pharmaceutical composition comprising a macrolide compound, such as tricyclic compound (I) or its pharmaceutically acceptable salt, a dissolution/absorption promoter, a pharmaceutical base, and optionally a compatibilizing agent and/or a thickener. It is satisfactory in stability and absorption kinetics and/or a low irritation potential.Type: ApplicationFiled: December 7, 2001Publication date: May 23, 2002Applicant: Fujisawa Pharmaceutical Co., Ltd.Inventors: Rinta Ibuki, Fumio Shimojo, Satoshi Ueda, Toshihiko Toyoda, Masayuki Yamanaka, Erika Yoshida
-
Patent number: 6387918Abstract: A pharmaceutical composition comprising a tricyclic compound (I) or its pharmaceutically acceptable salt, an oil substance, a surfactant, a hydrophilic substance, water, and optionally a pH control agent, with enhanced stability, absorbability and/or a low irritation potential, is provided.Type: GrantFiled: August 20, 1999Date of Patent: May 14, 2002Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Masayuki Yamanaka, Fumio Shimojo, Satoshi Ueda, Toshihiko Toyoda, Rinta Ibuki, Norio Ohnishi
-
Publication number: 20020044967Abstract: Providing an oral formulation of a macrolide compound where the dissolution of the macrolide compound is under sustained release; and a sustained-release formulation containing a composition in solid solution, where the macrolide compound is present at an amorphous state in a solid base.Type: ApplicationFiled: October 17, 2001Publication date: April 18, 2002Applicant: FUJISAWA PHARMACEUTICAL CO., LTD.Inventors: Kazunari Yamashita, Eiji Hashimoto, Yukihiro Nomura, Fumio Shimojo, Shigeki Tamura, Takeo Hirose, Satoshi Ueda, Takashi Saitoh, Rinta Ibuki, Toshio Ideno
-
Publication number: 20020032212Abstract: A pharmaceutical composition comprising a tricyclic compound (I) or its pharmaceutically acceptable salt, an oil substance, a surfactant, a hydrophilic substance, water, and optionally a pH control agent, with enhanced stability, absorbability and/or a low irritation potential, is provided.Type: ApplicationFiled: August 20, 1999Publication date: March 14, 2002Inventors: MASAYUKI YAMANAKA, FUMIO SHIMOJO, SATOSHI UEDA, TOSHIHIKO TOYODA, RINTA IBUKI, NORIO OHNISHI
-
Patent number: 6316473Abstract: Provided is a medicinal composition having a very satisfactory drug release profile and a very satisfactory drug absorption profile after oral administration characterized by its comprising an insoluble drug and two or more surfactants, at least one of the surfactants having as dissolved therein the insoluble drug and the other surfactant or surfactants.Type: GrantFiled: October 12, 1999Date of Patent: November 13, 2001Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Fumio Shimojo, Sumihisa Kimura, Takeo Hirose, Satoshi Ueda, Rinta Ibuki, Norio Ohnishi
-
Patent number: 5045553Abstract: The present invention relates to a pharmaceutical composition for percutaneous drug absorption which comprises 5-isopropyl 3-methyl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate, and ethanol and/or an unsaturated higher fatty acid and to a composition of matter which comprises ethanol and/or an unsaturated higher fatty acid and is capable of promoting percutaneous absorption of said dihydropyridine compound.Type: GrantFiled: June 17, 1988Date of Patent: September 3, 1991Assignee: Fujisawa Pharmaceutical Company, Ltd.Inventors: Yoshio Ueda, Takehisa Hata, Rinta Ibuki, Kazutake Kado, Hiroshi Ishikuro
-
Patent number: 4390694Abstract: A method for preparing stable crystals of a salt of Ceftizoxime which comprises mixing an aqueous solution of a salt of Ceftizoxime and isopropyl alcohol and collecting the precipitating crystals. Crystals obtained in this manner are more stable than the crystals obtained from prior art methods involving mixed solvents of water and ethanol.Type: GrantFiled: July 16, 1981Date of Patent: June 28, 1983Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Norio Ohnishi, Rinta Ibuki